Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients

• Published in: Japanese journal of ophthalmology 2023-11, Vol.67 (6), p.668-677
• Main Authors: Sakata, Rei, Mizoue, Shiro, Yoshikawa, Keiji, Adachi, Misato, Ohkubo, Shinji, Hamada, Naoki, Naito, Tomoko, Muramatsu, Tomoyuki, Hara, Takeshi, Asato, Ryo, Aihara, Makoto
• Format: Article
• Language: English
• Subjects: Acuity; Clinical Investigation; Complications; Glaucoma; Hypertension; Intraocular pressure; Medicine; Medicine & Public Health; Ophthalmology; Safety; Visual acuity
• ISSN: 0021-5155; 1613-2246
• DOI: 10.1007/s10384-023-01022-6

Purpose A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC). Study design This was a prospective, open-label, multicenter study. Patients and methods We enrolled Japanese patients with open-angle glaucoma. BBFC (Ailamide) was concomitantly administered to either the PG or the PG/beta FC group, and intraocular pressure (IOP) and safety were evaluated at 4 and 12 weeks. The groups were stratified into low and high IOP baseline groups based on the median baseline IOP. Results We enrolled 100 patients, 91 of whom completed the 12-week follow-up. The mean ages were 67.1 and 65.7 years in the PG group (n = 45, baseline IOP of 15.7 ± 2.3 mmHg) and the PG/beta FC group (n = 46, baseline IOP of 16.3 ± 2.3 mmHg), respectively. After BBFC administration, IOPs at 4 and 12 weeks were 13.0 ± 2.0 and 13.0 ± 2.6 mmHg ( P